Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

ALL/AML

Alopecia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

CLL/SLL

COPD

COVID-19

Cardiovascular

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Duchenne Muscular Dystrophy

Employers

Gastroenterology

Gene Therapy

Graft-vs-Host Disease (GVHD)

Heart Failure

Hemophilia

Idiopathic Pulmonary Fibrosis

Immuno-Oncology

Immunology

Leukemia and Lymphoma

Liver Cancer

Lung Cancer

Medicare

Mental Health

Multiple Myeloma

Multiple Sclerosis

Myasthenia Gravis

Myelodysplastic Syndromes

Myeloproliferative Neoplasms (MPN)

Non–Small Cell Lung Cancer

Obesity

Oncology

Ophthalmology

Ovarian Cancer

Population Health

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Reimbursement

Skin Cancer

Sleep

Soft Tissue Sarcoma

Type 1 Diabetes

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

Articles

Treatment escalation plans can successfully be implemented into routine oncology practice, according to one study. 

Implementing Treatment Escalation Plans in Oncology Care at Admission Boosts Uptake, Study Finds

Videos

Robert Zimmerman, MD, discussed the adverse side effects associated with glucagon-like peptide-1 (GLP1) and multi-agonist therapies, as well as explored the challenges in developing these interventions. 

Dr Robert Zimmerman Discusses Challenges, Adverse Effects of GLP-1 and Multi-Agonist Therapies

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

New data show that survival in patients living with postoperative colorectal cancer (CRC) could be predicted using a nomogram model.

Nomogram Model Could Predict Survival in Stage III CRC

New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.

What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Stakeholders

Academia

Health System

Payers

Providers

Topics

Institute for Value-Based Medicine

All Coverage

Event Coverage

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

1rem

Study Summary: Use of Enzalutamide for High-Risk, Nonmetastatic, Castration-Resistant Prostate Cancer (PROSPER)

Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018, 378(26):2465-2474. doi: 10.1056/NEJMoa1800536.

Articles